SEC Form 4 · accession 0001144204-16-076485
CASI Pharmaceuticals, Inc. · CASI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Keyong Ren
Officer — CEO and Director · Director
Period of report
Jan 19, 2016
Accepted (ET)
Jan 21, 2016 · 3:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000895051
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 19, 2016 | P | 7,537 | $0.73 | A | 7,537 | D | |
| Common Stock | Jan 19, 2016 | P | 1,100 | $0.74 | A | 8,637 | D | |
| Common Stock | Jan 19, 2016 | P | 6,063 | $0.72 | A | 14,700 | D | |
| Common Stock | Jan 19, 2016 | P | 300 | $0.71 | A | 15,000 | D |
Table II — derivative securities
No Table II lines on this filing.